Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Citius Oncology, Inc. (CTOR)
Company Research
Source: Yahoo! Finance
Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct offering on December 10, 2025, to strengthen cash position and support continued commercialization of LYMPHIR CRANFORD, N.J. Dec. 23, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal year ended September 30, 2025, and provided a business update. "2025 was a landmark year for Citius Oncology. With the U.S. commercial launch of LYMPHIR now underway, we have shifted from a pre-revenue to a revenue generating company," said Leonard Mazur, Chairman and CEO of Citius Oncology and parent company Citius Pharmaceuticals. "Our focus now is on driving adoption, delivering value to patients, and realizing the full commercial potential of our first-in-class therapy. We intend to leverage our adv
Show less
Read more
Impact Snapshot
Event Time:
CTOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTOR alerts
High impacting Citius Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CTOR
News
- Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdatePR Newswire
- Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesPR Newswire
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesPR Newswire
- Citius Oncology Expands LYMPHIRâ„¢ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimPR Newswire
CTOR
Sec Filings
- 12/23/25 - Form 8-K
- 12/23/25 - Form 10-K
- 12/22/25 - Form 4/A
- CTOR's page on the SEC website